Tag: MultiLINK™

A promising avenue is the targeting of CD37, a tetraspanin family member broadly expressed on malignant myeloid blasts but with limited expression on normal hematopoietic stem cells. Debio 1562M,** a second-generation novel antibody-drug conjugate (ADC) developed by Debiopharm, is designed to target CD37 and deliver a potent cytotoxic payload directly to tumor cells. Here, we review the preclinical development, mechanism of action, and therapeutic potential of Debio 1562M in AML and MDS.

Antibody-drug conjugate (ADC) innovation continues at a remarkable pace, as evidenced by the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held...